All In Biotech

NDA 018749 · Mission Pharma

Lithostat

Acetohydroxamic Acid · Oral · Urease Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jan 26, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

May 31, 1983

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

0 Phase 3, 0 recruiting

FAERS reports

47

11 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 8, 2026.

INDICATIONS AND USAGE Acetohydroxamic acid is indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection. AHA is intended to decrease urinary ammonia and alkalinity, but it should not be used in lieu of curative surgical treatment (for patients with stones) or antimicrobial treatment. Long-term treatment with AHA may be warranted to maintain urease inhibition as long as urea-splitting infection is present. Experience with AHA does not go beyond 7 years. A patient package insert should be distributed to each patient who receives AHA.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 31, 1983 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • LITHOSTAT · ACETOHYDROXAMIC ACID 250MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Acetohydroxamic Acid" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache12
  • decreased appetite10
  • tremor9
  • asthenia5
  • nausea5
  • confusional state4
  • death4
  • fatigue4
  • rash4
  • somnolence4
  • abdominal pain upper3
  • alopecia3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20072
20131
20163
201713
201812
20196
20204
20216

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lithostat (Acetohydroxamic Acid)

2024 spending

$651K

Beneficiaries

242

1,360 claims

Per beneficiary

$2,688

$6.73 per unit

View as table
YearSpending
2020$742,914
2021$973,033
2022$701,602
2023$572,333
2024$650,584

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Mission Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.